Saltar al contenido
Merck

VEGF-A in serum protects against memory impairment in APP/PS1 transgenic mice by blocking neutrophil infiltration.

Molecular psychiatry (2023-06-07)
Fangfang Qi, Zejie Zuo, Kaishun Hu, Rui Wang, Tong Wu, Hao Liu, Jiaoling Tang, Qingbo Wang, Yufeng Xie, Liren Tan, Yunjie Yang, Xiaoran Zhang, Jiaying Zheng, Jie Xu, Zhibin Yao, Shengwen Wang, Long-Jun Wu, Kaihua Guo
RESUMEN

Activation of innate immunity in the brain is a prominent feature of Alzheimer's disease (AD). The present study investigated the regulation of innate immunity by wild-type serum injection in a transgenic AD mouse model. We found that treatment with wild-type mouse serum significantly reduced the number of neutrophils and microglial reactivity in the brains of APP/PS1 mice. Mimicking this effect, neutrophil depletion via Ly6G neutralizing antibodies resulted in improvements in AD brain functions. Serum proteomic analysis identified vascular endothelial growth factor-A (VEGF-A) and chemokine (C-X-C motif) ligand 1 (CXCL1) as factors enriched in serum samples, which are crucial for neutrophil migration and chemotaxis, leukocyte migration, and cell chemotaxis. Exogenous VEGF-A reversed amyloid β (Aβ)-induced decreases in cyclin-dependent kinase 5 (Cdk5) and increases in CXCL1 in vitro and blocked neutrophil infiltration into the AD brain. Endothelial Cdk5 overexpression conferred an inhibitory effect on CXCL1 and neutrophil infiltration, thereby restoring memory abilities in APP/PS1 mice. Our findings uncover a previously unknown link between blood-derived VEGF signaling and neutrophil infiltration and support targeting endothelial Cdk5 signaling as a potential therapeutic strategy for AD.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Monoclonal Anti-Synaptophysin antibody produced in mouse, clone SVP-38, ascites fluid
Sigma-Aldrich
Anti-β-Amyloid antibody, Mouse monoclonal, clone BAM-10, ascites fluid